Literature DB >> 28196556

Approach to atypical Alzheimer's disease and case studies of the major subtypes.

Bradford C Dickerson1, Scott M McGinnis1, Chenjie Xia1, Bruce H Price1, Alireza Atri2, Melissa E Murray3, Mario F Mendez4, David A Wolk5.   

Abstract

Alzheimer's disease (AD) has long been recognized as a heterogeneous illness, with a common clinical presentation of progressive amnesia and less common "atypical" clinical presentations, including syndromes dominated by visual, aphasic, "frontal," or apraxic symptoms. Our knowledge of atypical clinical phenotypes of AD comes from clinicopathologic studies, but with the growing use of in vivo molecular biomarkers of amyloid and tau pathology, we are beginning to recognize that these syndromes may not be as rare as once thought. When a clinician is evaluating a patient whose clinical phenotype is dominated by progressive aphasia, complex visual impairment, or other neuropsychiatric symptoms with relative sparing of memory, the differential diagnosis may be broader and a confident diagnosis of an atypical form of AD may require the use of molecular biomarkers. Despite the evolving sophistication in our diagnostic tools, and the acknowledgment of atypical AD syndromes in the 2011 revised diagnostic criteria for AD, the assessment of such patients still poses substantial challenges. We use a case-based approach to review the clinical and imaging phenotypes of a series of patients with typical and atypical AD, and discuss our current approach to their evaluation. One day, we hope that regardless of whether a patient exhibits typical or atypical symptoms of AD pathology, we will be able to identify the condition at a prodromal phase and institute a combination of symptomatic and disease-modifying therapies to support cognitive processes, function, and behavior, and slow or halt progression to dementia.

Entities:  

Keywords:  Alzheimer’s disease; biomarkers; corticobasal syndrome; mild cognitive impairment; posterior cortical atrophy; primary progressive aphasia

Mesh:

Year:  2017        PMID: 28196556      PMCID: PMC5557706          DOI: 10.1017/S109285291600047X

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  75 in total

1.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases.

Authors:  C J Galton; K Patterson; J H Xuereb; J R Hodges
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

Review 3.  Neural substrates of cognitive and behavioral deficits in atypical Alzheimer's disease.

Authors:  Armin von Gunten; Constantin Bouras; Enikö Kövari; Panteleimon Giannakopoulos; Patrick R Hof
Journal:  Brain Res Rev       Date:  2006-01-18

Review 4.  Clinical practice. Mild cognitive impairment.

Authors:  Ronald C Petersen
Journal:  N Engl J Med       Date:  2011-06-09       Impact factor: 91.245

5.  Progressive aphasia: a precursor of global dementia?

Authors:  J Green; J C Morris; J Sandson; D W McKeel; J W Miller
Journal:  Neurology       Date:  1990-03       Impact factor: 9.910

6.  Relating anatomy to function in Alzheimer's disease: neuropsychological profiles predict regional neuropathology 5 years later.

Authors:  S M Kanne; D A Balota; M Storandt; D W McKeel; J C Morris
Journal:  Neurology       Date:  1998-04       Impact factor: 9.910

7.  In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings.

Authors:  Maïté Formaglio; Nicolas Costes; Jérémie Seguin; Yannick Tholance; Didier Le Bars; Isabelle Roullet-Solignac; Bernadette Mercier; Pierre Krolak-Salmon; Alain Vighetto
Journal:  J Neurol       Date:  2011-04-10       Impact factor: 4.849

Review 8.  Tau imaging: early progress and future directions.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Colin L Masters; Christopher C Rowe
Journal:  Lancet Neurol       Date:  2015-01       Impact factor: 44.182

9.  Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease.

Authors:  B H Price; H Gurvit; S Weintraub; C Geula; E Leimkuhler; M Mesulam
Journal:  Arch Neurol       Date:  1993-09

10.  Distinct tau prion strains propagate in cells and mice and define different tauopathies.

Authors:  David W Sanders; Sarah K Kaufman; Sarah L DeVos; Apurwa M Sharma; Hilda Mirbaha; Aimin Li; Scarlett J Barker; Alex C Foley; Julian R Thorpe; Louise C Serpell; Timothy M Miller; Lea T Grinberg; William W Seeley; Marc I Diamond
Journal:  Neuron       Date:  2014-05-22       Impact factor: 17.173

View more
  23 in total

1.  Montreal Cognitive Assessment (MoCA) Performance and Domain-Specific Index Scores in Amnestic Versus Aphasic Dementia.

Authors:  Jessica L Wood; Sandra Weintraub; Christina Coventry; Jiahui Xu; Hui Zhang; Emily Rogalski; Marek-Marsel Mesulam; Tamar Gefen
Journal:  J Int Neuropsychol Soc       Date:  2020-05-19       Impact factor: 2.892

2.  Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Authors:  Ganesh M Babulal; Yakeel T Quiroz; Benedict C Albensi; Eider Arenaza-Urquijo; Arlene J Astell; Claudio Babiloni; Alex Bahar-Fuchs; Joanne Bell; Gene L Bowman; Adam M Brickman; Gaël Chételat; Carrie Ciro; Ann D Cohen; Peggye Dilworth-Anderson; Hiroko H Dodge; Simone Dreux; Steven Edland; Anna Esbensen; Lisbeth Evered; Michael Ewers; Keith N Fargo; Juan Fortea; Hector Gonzalez; Deborah R Gustafson; Elizabeth Head; James A Hendrix; Scott M Hofer; Leigh A Johnson; Roos Jutten; Kerry Kilborn; Krista L Lanctôt; Jennifer J Manly; Ralph N Martins; Michelle M Mielke; Martha Clare Morris; Melissa E Murray; Esther S Oh; Mario A Parra; Robert A Rissman; Catherine M Roe; Octavio A Santos; Nikolaos Scarmeas; Lon S Schneider; Nicole Schupf; Sietske Sikkes; Heather M Snyder; Hamid R Sohrabi; Yaakov Stern; Andre Strydom; Yi Tang; Graciela Muniz Terrera; Charlotte Teunissen; Debora Melo van Lent; Michael Weinborn; Linda Wesselman; Donna M Wilcock; Henrik Zetterberg; Sid E O'Bryant
Journal:  Alzheimers Dement       Date:  2018-12-13       Impact factor: 21.566

3.  Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum.

Authors:  Deepti Putcha; Bradford C Dickerson; Michael Brickhouse; Keith A Johnson; Reisa A Sperling; Kathryn V Papp
Journal:  Neuropsychologia       Date:  2020-02-10       Impact factor: 3.139

Review 4.  Diagnostic evaluation and monitoring of patients with posterior cortical atrophy.

Authors:  Bonnie Wong; Diane E Lucente; Julie MacLean; Jaya Padmanabhan; Megan Quimby; Katherine D Brandt; Deepti Putcha; Janet Sherman; Matthew P Frosch; Scott McGinnis; Bradford C Dickerson
Journal:  Neurodegener Dis Manag       Date:  2019-08-08

5.  Case Study 1: A 55-Year-Old Woman With Progressive Cognitive, Perceptual, and Motor Impairments.

Authors:  Scott M McGinnis; Andrew M Stern; Jared K Woods; Matthew Torre; Mel B Feany; Michael B Miller; David A Silbersweig; Seth A Gale; Kirk R Daffner
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2021-11-12       Impact factor: 2.198

6.  Molecular Imaging Biomarkers in Dementia: Amyloid and tau PET imaging aids evaluation of patients suspected of having Alzheimer disease or other dementias.

Authors:  Brad Dickerson; Alireza Atri
Journal:  Pract Neurol (Fort Wash Pa)       Date:  2020 Nov-Dec

7.  Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease.

Authors:  Jeffrey S Phillips; Fulvio Da Re; David J Irwin; Corey T McMillan; Sanjeev N Vaishnavi; Sharon X Xie; Edward B Lee; Philip A Cook; James C Gee; Leslie M Shaw; John Q Trojanowski; David A Wolk; Murray Grossman
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

Review 8.  New insights into atypical Alzheimer's disease in the era of biomarkers.

Authors:  Jonathan Graff-Radford; Keir X X Yong; Liana G Apostolova; Femke H Bouwman; Maria Carrillo; Bradford C Dickerson; Gil D Rabinovici; Jonathan M Schott; David T Jones; Melissa E Murray
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

9.  ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Katheryn A Q Cousins; David J Irwin; David A Wolk; Edward B Lee; Leslie M J Shaw; John Q Trojanowski; Fulvio Da Re; Garrett S Gibbons; Murray Grossman; Jeffrey S Phillips
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

10.  More Atypical than Atypical Alzheimer's Disease Phenotypes: A Treviso Dementia (TREDEM) Registry Case Report.

Authors:  Maurizio Gallucci; Anna Paola Mazzarolo; Lucia Focella; Elisa Berlin; Vittorio Fiore; Francesco Di Paola; Matteo Bendini; Gianluigi Zanusso; Chiara Fenoglio; Daniela Galimberti; Laura Bonanni
Journal:  J Alzheimers Dis Rep       Date:  2021-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.